Development and Validation of a Prognostic Risk Model Based on Nature Killer Cells for Serous Ovarian Cancer
Abstract
:1. Introduction
2. Materials and Methods
2.1. Data Collection
2.2. Analysis of scRNA-seq Dataset and Identification of NK-Cell DEGs
2.3. Construction and Validation of the Prognostic Risk Model Based on NK-Cell DEGs
2.4. Functional Enrichment Analysis
2.5. Immune Activities Assessment
2.6. Quantity and Functional State of Immunocytes Evaluation
2.7. Statistical Analyses
3. Results
3.1. Identification of NK-Cell DEGs by scRNA-seq Dataset Analysis
3.2. Development of a Prognostic Risk Model Based on the NK-Cell DEGs
3.3. External Validation of the Prognostic Risk Model in Independent Cohorts
3.4. The Prognostic Risk Model Acted as an Independent Prognostic Factor
3.5. Functional Enrichment Analysis of Genes Correlated with the Prognostic Risk Model
3.6. Assessment of Immune Activities in Tumor Microenvironment
3.7. Association of the Prognostic Risk Model with Quantity and Functional State of Immunocytes
4. Discussion
Supplementary Materials
Author Contributions
Funding
Data Availability Statement
Acknowledgments
Conflicts of Interest
References
- Jayson, G.C.; Kohn, E.C.; Kitchener, H.C.; Ledermann, J.A. Ovarian Cancer. Lancet 2014, 384, 1376–1388. [Google Scholar] [CrossRef] [PubMed]
- Bowtell, D.D.; Böhm, S.; Ahmed, A.A.; Aspuria, P.-J.; Bast, R.C.; Beral, V.; Berek, J.S.; Birrer, M.J.; Blagden, S.; Bookman, M.A.; et al. Rethinking Ovarian Cancer II: Reducing Mortality from High-Grade Serous Ovarian Cancer. Nat. Rev. Cancer 2015, 15, 668–679. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Pardoll, D.M. The Blockade of Immune Checkpoints in Cancer Immunotherapy. Nat. Rev. Cancer 2012, 12, 252–264. [Google Scholar] [CrossRef] [Green Version]
- Hamanishi, J.; Mandai, M.; Iwasaki, M.; Okazaki, T.; Tanaka, Y.; Yamaguchi, K.; Higuchi, T.; Yagi, H.; Takakura, K.; Minato, N.; et al. Programmed Cell Death 1 Ligand 1 and Tumor-Infiltrating CD8+ T Lymphocytes Are Prognostic Factors of Human Ovarian Cancer. Proc. Natl. Acad. Sci. USA 2007, 104, 3360–3365. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Disis, M.L.; Taylor, M.H.; Kelly, K.; Beck, J.T.; Gordon, M.; Moore, K.M.; Patel, M.R.; Chaves, J.; Park, H.; Mita, A.C.; et al. Efficacy and Safety of Avelumab for Patients With Recurrent or Refractory Ovarian Cancer: Phase 1b Results From the JAVELIN Solid Tumor Trial. JAMA Oncol. 2019, 5, 393–401. [Google Scholar] [CrossRef] [Green Version]
- Hwang, W.-T.; Adams, S.F.; Tahirovic, E.; Hagemann, I.S.; Coukos, G. Prognostic Significance of Tumor-Infiltrating T Cells in Ovarian Cancer: A Meta-Analysis. Gynecol. Oncol. 2012, 124, 192–198. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Jiménez-Sánchez, A.; Memon, D.; Pourpe, S.; Veeraraghavan, H.; Li, Y.; Vargas, H.A.; Gill, M.B.; Park, K.J.; Zivanovic, O.; Konner, J.; et al. Heterogeneous Tumor-Immune Microenvironments among Differentially Growing Metastases in an Ovarian Cancer Patient. Cell 2017, 170, 927–938. [Google Scholar] [CrossRef] [Green Version]
- Kandalaft, L.E.; Motz, G.T.; Duraiswamy, J.; Coukos, G. Tumor Immune Surveillance and Ovarian Cancer: Lessons on Immune Mediated Tumor Rejection or Tolerance. Cancer Metastasis Rev. 2011, 30, 141–151. [Google Scholar] [CrossRef]
- Zhang, L.; Conejo-Garcia, J.R.; Katsaros, D.; Gimotty, P.A.; Massobrio, M.; Regnani, G.; Makrigiannakis, A.; Gray, H.; Schlienger, K.; Liebman, M.N.; et al. Intratumoral T Cells, Recurrence, and Survival in Epithelial Ovarian Cancer. N. Engl. J. Med. 2003, 348, 203–213. [Google Scholar] [CrossRef] [Green Version]
- Hugo, W.; Zaretsky, J.M.; Sun, L.; Song, C.; Moreno, B.H.; Hu-Lieskovan, S.; Berent-Maoz, B.; Pang, J.; Chmielowski, B.; Cherry, G.; et al. Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma. Cell 2016, 165, 35–44. [Google Scholar] [CrossRef] [Green Version]
- Hsu, J.; Hodgins, J.J.; Marathe, M.; Nicolai, C.J.; Bourgeois-Daigneault, M.-C.; Trevino, T.N.; Azimi, C.S.; Scheer, A.K.; Randolph, H.E.; Thompson, T.W.; et al. Contribution of NK Cells to Immunotherapy Mediated by PD-1/PD-L1 Blockade. J. Clin. Investig. 2018, 128, 4654–4668. [Google Scholar] [CrossRef]
- Concha-Benavente, F.; Kansy, B.; Moskovitz, J.; Moy, J.; Chandran, U.; Ferris, R.L. PD-L1 Mediates Dysfunction in Activated PD-1+ NK Cells in Head and Neck Cancer Patients. Cancer Immunol. Res. 2018, 6, 1548–1560. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Sun, Y.; Yao, Z.; Zhao, Z.; Xiao, H.; Xia, M.; Zhu, X.; Jiang, X.; Sun, C. Natural Killer Cells Inhibit Metastasis of Ovarian Carcinoma Cells and Show Therapeutic Effects in a Murine Model of Ovarian Cancer. Exp. Ther. Med. 2018, 16, 1071–1078. [Google Scholar] [CrossRef] [PubMed]
- Tang, F.; Barbacioru, C.; Wang, Y.; Nordman, E.; Lee, C.; Xu, N.; Wang, X.; Bodeau, J.; Tuch, B.B.; Siddiqui, A.; et al. MRNA-Seq Whole-Transcriptome Analysis of a Single Cell. Nat. Methods 2009, 6, 377–382. [Google Scholar] [CrossRef] [PubMed]
- Hashimshony, T.; Senderovich, N.; Avital, G.; Klochendler, A.; de Leeuw, Y.; Anavy, L.; Gennert, D.; Li, S.; Livak, K.J.; Rozenblatt-Rosen, O.; et al. CEL-Seq2: Sensitive Highly-Multiplexed Single-Cell RNA-Seq. Genome Biol. 2016, 17, 77. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Picelli, S.; Faridani, O.R.; Björklund, A.K.; Winberg, G.; Sagasser, S.; Sandberg, R. Full-Length RNA-Seq from Single Cells Using Smart-Seq2. Nat. Protoc. 2014, 9, 171–181. [Google Scholar] [CrossRef]
- Ramsköld, D.; Luo, S.; Wang, Y.-C.; Li, R.; Deng, Q.; Faridani, O.R.; Daniels, G.A.; Khrebtukova, I.; Loring, J.F.; Laurent, L.C.; et al. Full-Length MRNA-Seq from Single-Cell Levels of RNA and Individual Circulating Tumor Cells. Nat. Biotechnol. 2012, 30, 777–782. [Google Scholar] [CrossRef] [Green Version]
- Zheng, G.X.Y.; Terry, J.M.; Belgrader, P.; Ryvkin, P.; Bent, Z.W.; Wilson, R.; Ziraldo, S.B.; Wheeler, T.D.; McDermott, G.P.; Zhu, J.; et al. Massively Parallel Digital Transcriptional Profiling of Single Cells. Nat. Commun. 2017, 8, 14049. [Google Scholar] [CrossRef] [Green Version]
- Wang, L.; Sun, W.; Zhang, G.; Huo, J.; Tian, Y.; Zhang, Y.; Yang, X.; Liu, Y. T-Cell Activation Is Associated with High-Grade Serous Ovarian Cancer Survival. J. Obstet. Gynaecol. Res. 2022, 48, 2189–2197. [Google Scholar] [CrossRef]
- Zhang, G.; Xu, Q.; Zhang, X.; Yang, M.; Wang, Y.; He, M.; Lu, J.; Liu, H. Spatial Cytotoxic and Memory T Cells in Tumor Predict Superior Survival Outcomes in Patients with High-grade Serous Ovarian Cancer. Cancer Med. 2021, 10, 3905–3918. [Google Scholar] [CrossRef]
- Liang, L.; Yu, J.; Li, J.; Li, N.; Liu, J.; Xiu, L.; Zeng, J.; Wang, T.; Wu, L. Integration of ScRNA-Seq and Bulk RNA-Seq to Analyse the Heterogeneity of Ovarian Cancer Immune Cells and Establish a Molecular Risk Model. Front. Oncol. 2021, 11, 711020. [Google Scholar] [CrossRef]
- Liu, C.; Zhang, Y.; Li, X.; Wang, D. Ovarian Cancer-Specific Dysregulated Genes with Prognostic Significance: ScRNA-Seq with Bulk RNA-Seq Data and Experimental Validation. Ann. N. Y. Acad. Sci. 2022, 1512, 154–173. [Google Scholar] [CrossRef] [PubMed]
- Cursons, J.; Souza-Fonseca-Guimaraes, F.; Foroutan, M.; Anderson, A.; Hollande, F.; Hediyeh-Zadeh, S.; Behren, A.; Huntington, N.D.; Davis, M.J. A Gene Signature Predicting Natural Killer Cell Infiltration and Improved Survival in Melanoma Patients. Cancer Immunol. Res. 2019, 7, 1162–1174. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Song, P.; Li, W.; Guo, L.; Ying, J.; Gao, S.; He, J. Identification and Validation of a Novel Signature Based on NK Cell Marker Genes to Predict Prognosis and Immunotherapy Response in Lung Adenocarcinoma by Integrated Analysis of Single-Cell and Bulk RNA-Sequencing. Front. Immunol. 2022, 13, 850745. [Google Scholar] [CrossRef]
- Hao, Y.; Hao, S.; Andersen-Nissen, E.; Mauck, W.M.; Zheng, S.; Butler, A.; Lee, M.J.; Wilk, A.J.; Darby, C.; Zager, M.; et al. Integrated Analysis of Multimodal Single-Cell Data. Cell 2021, 184, 3573–3587.e29. [Google Scholar] [CrossRef] [PubMed]
- Xu, J.; Fang, Y.; Chen, K.; Li, S.; Tang, S.; Ren, Y.; Cen, Y.; Fei, W.; Zhang, B.; Shen, Y.; et al. Single-Cell RNA Sequencing Reveals the Tissue Architecture in Human High-Grade Serous Ovarian Cancer. Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res. 2022, 28, 3590–3602. [Google Scholar] [CrossRef]
- Franzén, O.; Gan, L.-M.; Björkegren, J.L.M. PanglaoDB: A Web Server for Exploration of Mouse and Human Single-Cell RNA Sequencing Data. Database 2019, 2019, baz046. [Google Scholar] [CrossRef] [Green Version]
- Therneau, T.M.; Grambsch, P.M. Modeling Survival Data: Extending the Cox Model; Springer: New York, NY, USA, 2000; ISBN 0-387-98784-3. [Google Scholar]
- Friedman, J.H.; Hastie, T.; Tibshirani, R. Regularization Paths for Generalized Linear Models via Coordinate Descent. J. Stat. Softw. 2010, 33, 1–22. [Google Scholar] [CrossRef] [Green Version]
- Kassambara, A.; Kosinski, M.; Biecek, P.; Fabian, S. Survminer: Drawing Survival Curves Using ‘Ggplot2’. R Package Version 0.4.9. 2021. Available online: https://CRAN.Rproject.org/package=survminer (accessed on 30 September 2022).
- Heagerty, P.J.; Lumley, T.; Pepe, M.S. Time-Dependent ROC Curves for Censored Survival Data and a Diagnostic Marker. Biometrics 2000, 56, 337–344. [Google Scholar] [CrossRef]
- Yu, G.; Wang, L.-G.; Han, Y.; He, Q.-Y. ClusterProfiler: An R Package for Comparing Biological Themes Among Gene Clusters. OMICS J. Integr. Biol. 2012, 16, 284–287. [Google Scholar] [CrossRef]
- Carlson, M. Org.Hs.Eg.Db: Genome Wide Annotation for Human. R Package Version 3.15.0. 2022. Available online: https://bioconductor.org/packages/release/data/annotation/html/org.Hs.eg.db.html (accessed on 27 September 2022).
- Rody, A.; Holtrich, U.; Pusztai, L.; Liedtke, C.; Gaetje, R.; Ruckhaeberle, E.; Solbach, C.; Hanker, L.; Ahr, A.; Metzler, D.; et al. T-Cell Metagene Predicts a Favorable Prognosis in Estrogen Receptor-Negative and HER2-Positive Breast Cancers. Breast Cancer Res. 2009, 11, R15. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Hänzelmann, S.; Castelo, R.; Guinney, J. GSVA: Gene Set Variation Analysis for Microarray and RNA-Seq Data. BMC Bioinform. 2013, 14, 7. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Yoshihara, K.; Shahmoradgoli, M.; Martínez, E.; Vegesna, R.; Kim, H.; Torres-Garcia, W.; Treviño, V.; Shen, H.; Laird, P.W.; Levine, D.A.; et al. Inferring Tumour Purity and Stromal and Immune Cell Admixture from Expression Data. Nat. Commun. 2013, 4, 2612. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Newman, A.M.; Liu, C.L.; Green, M.R.; Gentles, A.J.; Feng, W.; Xu, Y.; Hoang, C.D.; Diehn, M.; Alizadeh, A.A. Robust Enumeration of Cell Subsets from Tissue Expression Profiles. Nat. Methods 2015, 12, 453–457. [Google Scholar] [CrossRef] [Green Version]
- Fu, J.; Li, K.; Zhang, W.; Wan, C.; Zhang, J.; Jiang, P.; Liu, X.S. Large-Scale Public Data Reuse to Model Immunotherapy Response and Resistance. Genome Med. 2020, 12, 21. [Google Scholar] [CrossRef] [Green Version]
- Jiang, P.; Gu, S.; Pan, D.; Fu, J.; Sahu, A.; Hu, X.; Li, Z.; Traugh, N.; Bu, X.; Li, B.; et al. Signatures of T Cell Dysfunction and Exclusion Predict Cancer Immunotherapy Response. Nat. Med. 2018, 24, 1550–1558. [Google Scholar] [CrossRef]
- Khan, M.; Arooj, S.; Wang, H. NK Cell-Based Immune Checkpoint Inhibition. Front. Immunol. 2020, 11, 167. [Google Scholar] [CrossRef]
- Garzetti, G.G.; Cignitti, M.; Ciavattini, A.; Fabris, N.; Romanini, C. Natural Killer Cell Activity and Progression-Free Survival in Ovarian Cancer. Gynecol. Obstet. Investig. 1993, 35, 118–120. [Google Scholar] [CrossRef]
- Tiper, I.V.; Temkin, S.M.; Spiegel, S.; Goldblum, S.E.; Giuntoli, R.L.; Oelke, M.; Schneck, J.P.; Webb, T.J. VEGF Potentiates GD3-Mediated Immunosuppression by Human Ovarian Cancer Cells. Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res. 2016, 22, 4249–4258. [Google Scholar] [CrossRef] [Green Version]
- Ovarian Tumor Tissue Analysis (OTTA) Consortium; Goode, E.L.; Block, M.S.; Kalli, K.R.; Vierkant, R.A.; Chen, W.; Fogarty, Z.C.; Gentry-Maharaj, A.; Tołoczko, A.; Hein, A.; et al. Dose-Response Association of CD8+ Tumor-Infiltrating Lymphocytes and Survival Time in High-Grade Serous Ovarian Cancer. JAMA Oncol. 2017, 3, e173290. [Google Scholar] [CrossRef] [Green Version]
- Bösmüller, H.-C.; Wagner, P.; Peper, J.K.; Schuster, H.; Pham, D.L.; Greif, K.; Beschorner, C.; Rammensee, H.-G.; Stevanović, S.; Fend, F.; et al. Combined Immunoscore of CD103 and CD3 Identifies Long-Term Survivors in High-Grade Serous Ovarian Cancer. Int. J. Gynecol. Cancer Off. J. Int. Gynecol. Cancer Soc. 2016, 26, 671–679. [Google Scholar] [CrossRef] [PubMed]
- Wang, J.; Zhu, M.; Zhou, X.; Wang, T.; Xi, Y.; Jing, Z.; Xi, W. MiR-140-3p Inhibits Natural Killer Cytotoxicity to Human Ovarian Cancer via Targeting MAPK1. J. Biosci. 2020, 45, 66. [Google Scholar] [CrossRef] [PubMed]
- Hedges, J.F.; Kimmel, E.; Snyder, D.T.; Jerome, M.; Jutila, M.A. SLC11A1 Is Expressed by Innate Lymphocytes and Augments Their Activation. J. Immunol. 2013, 190, 4263–4273. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Connor, E.V.; Saygin, C.; Braley, C.; Wiechert, A.C.; Karunanithi, S.; Crean-Tate, K.; Abdul-Karim, F.W.; Michener, C.M.; Rose, P.G.; Lathia, J.D.; et al. Thy-1 Predicts Poor Prognosis and Is Associated with Self-Renewal in Ovarian Cancer. J. Ovarian Res. 2019, 12, 112. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Chen, W.-C.; Hsu, H.-P.; Li, C.-Y.; Yang, Y.-J.; Hung, Y.-H.; Cho, C.-Y.; Wang, C.-Y.; Weng, T.-Y.; Lai, M.-D. Cancer Stem Cell Marker CD90 Inhibits Ovarian Cancer Formation via Β3 Integrin. Int. J. Oncol. 2016, 49, 1881–1889. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Mosig, R.A.; Lobl, M.; Senturk, E.; Shah, H.; Cohen, S.; Chudin, E.; Fruscio, R.; Marchini, S.; D’Incalci, M.; Sachidanandam, R.; et al. IGFBP-4 Tumor and Serum Levels Are Increased across All Stages of Epithelial Ovarian Cancer. J. Ovarian Res. 2012, 5, 3. [Google Scholar] [CrossRef] [Green Version]
- Zheng, R.; Chen, W.; Xia, W.; Zheng, J.; Zhou, Q. The Prognostic Values of the Insulin-Like Growth Factor Binding Protein Family in Ovarian Cancer. BioMed Res. Int. 2020, 2020, 7658782. [Google Scholar] [CrossRef]
- Wilton, K.M.; Overlee, B.L.; Billadeau, D.D. NKG2D–DAP10 Signaling Recruits EVL to the Cytotoxic Synapse to Generate F-Actin and Promote NK Cell Cytotoxicity. J. Cell Sci. 2019, 133, jcs230508. [Google Scholar] [CrossRef] [Green Version]
- Kedves, A.T.; Gleim, S.; Liang, X.; Bonal, D.M.; Sigoillot, F.; Harbinski, F.; Sanghavi, S.; Benander, C.; George, E.; Gokhale, P.C.; et al. Recurrent Ubiquitin B Silencing in Gynecological Cancers Establishes Dependence on Ubiquitin C. J. Clin. Investig. 2017, 127, 4554–4568. [Google Scholar] [CrossRef] [Green Version]
- Xue, B.; Li, S.; Jin, X.; Liu, L. Bioinformatics Analysis of MRNA and MiRNA Microarray to Identify the Key MiRNA-MRNA Pairs in Cisplatin-Resistant Ovarian Cancer. BMC Cancer 2021, 21, 452. [Google Scholar] [CrossRef]
- Burgers, P.P.; Ma, Y.; Margarucci, L.; Mackey, M.; van der Heyden, M.A.G.; Ellisman, M.; Scholten, A.; Taylor, S.S.; Heck, A.J.R. A Small Novel A-Kinase Anchoring Protein (AKAP) That Localizes Specifically Protein Kinase A-Regulatory Subunit I (PKA-RI) to the Plasma Membrane. J. Biol. Chem. 2012, 287, 43789–43797. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Qiu, X.; Zhu, X.; Zhang, L.; Mao, Y.; Zhang, J.; Hao, P.; Li, G.; Lv, P.; Li, Z.; Sun, X.; et al. Human Epithelial Cancers Secrete Immunoglobulin g with Unidentified Specificity to Promote Growth and Survival of Tumor Cells. Cancer Res. 2003, 63, 6488–6495. [Google Scholar] [PubMed]
- Babbage, G.; Ottensmeier, C.H.; Blaydes, J.; Stevenson, F.K.; Sahota, S.S. Immunoglobulin Heavy Chain Locus Events and Expression of Activation-Induced Cytidine Deaminase in Epithelial Breast Cancer Cell Lines. Cancer Res. 2006, 66, 3996–4000. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Ruiter, D.J.; Mattijssen, V.; Broecker, E.B.; Ferrone, S. MHC Antigens in Human Melanomas. Semin. Cancer Biol. 1991, 2, 35–45. [Google Scholar]
- Wang, J.; Chen, R.; Liu, X.; Shen, J.; Yan, Y.; Gao, Y.; Tao, T.; Shi, J. Hck Promotes Neuronal Apoptosis Following Intracerebral Hemorrhage. Cell. Mol. Neurobiol. 2017, 37, 251–261. [Google Scholar] [CrossRef]
- Rohrs, J.A.; Wang, P.; Finley, S.D. Predictive Model of Lymphocyte-Specific Protein Tyrosine Kinase (LCK) Autoregulation. Cell. Mol. Bioeng. 2016, 9, 351–367. [Google Scholar] [CrossRef] [Green Version]
- Kumar Singh, P.; Kashyap, A.; Silakari, O. Exploration of the Therapeutic Aspects of Lck: A Kinase Target in Inflammatory Mediated Pathological Conditions. Biomed. Pharmacother. Biomedecine Pharmacother. 2018, 108, 1565–1571. [Google Scholar] [CrossRef]
- Hoogstad-van Evert, J.S.; Maas, R.J.; van der Meer, J.; Cany, J.; van der Steen, S.; Jansen, J.H.; Miller, J.S.; Bekkers, R.; Hobo, W.; Massuger, L.; et al. Peritoneal NK Cells Are Responsive to IL-15 and Percentages Are Correlated with Outcome in Advanced Ovarian Cancer Patients. Oncotarget 2018, 9, 34810–34820. [Google Scholar] [CrossRef] [Green Version]
- Wang, J.-J.; Siu, M.K.-Y.; Jiang, Y.-X.; Chan, D.W.; Cheung, A.N.-Y.; Ngan, H.Y.-S.; Chan, K.K.-L. Infiltration of T Cells Promotes the Metastasis of Ovarian Cancer Cells via the Modulation of Metastasis-Related Genes and PD-L1 Expression. Cancer Immunol. Immunother. 2020, 69, 2275–2289. [Google Scholar] [CrossRef]
- Wherry, E.J.; Kurachi, M. Molecular and Cellular Insights into T Cell Exhaustion. Nat. Rev. Immunol. 2015, 15, 486–499. [Google Scholar] [CrossRef]
- da Silva, I.P.; Gallois, A.; Jimenez-Baranda, S.; Khan, S.; Anderson, A.C.; Kuchroo, V.K.; Osman, I.; Bhardwaj, N. Reversal of NK-Cell Exhaustion in Advanced Melanoma by Tim-3 Blockade. Cancer Immunol. Res. 2014, 2, 410–422. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Shimasaki, N.; Jain, A.; Campana, D. NK Cells for Cancer Immunotherapy. Nat. Rev. Drug Discov. 2020, 19, 200–218. [Google Scholar] [CrossRef] [PubMed]
- Gray, J.D.; Hirokawa, M.; Horwitz, D.A. The Role of Transforming Growth Factor Beta in the Generation of Suppression: An Interaction between CD8+ T and NK Cells. J. Exp. Med. 1994, 180, 1937–1942. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Ludigs, K.; Jandus, C.; Utzschneider, D.T.; Staehli, F.; Bessoles, S.; Dang, A.T.; Rota, G.; Castro, W.; Zehn, D.; Vivier, E.; et al. NLRC5 Shields T Lymphocytes from NK-Cell-Mediated Elimination under Inflammatory Conditions. Nat. Commun. 2016, 7, 10554. [Google Scholar] [CrossRef] [Green Version]
- Ardolino, M.; Zingoni, A.; Cerboni, C.; Cecere, F.; Soriani, A.; Iannitto, M.L.; Santoni, A. DNAM-1 Ligand Expression on Ag-Stimulated T Lymphocytes Is Mediated by ROS-Dependent Activation of DNA-Damage Response: Relevance for NK-T Cell Interaction. Blood 2011, 117, 4778–4786. [Google Scholar] [CrossRef]
- Peng, P.; Lou, Y.; Wang, S.; Wang, J.; Zhang, Z.; Du, P.; Zheng, J.; Liu, P.; Xu, L.X. Activated NK Cells Reprogram MDSCs via NKG2D-NKG2DL and IFN-γ to Modulate Antitumor T-Cell Response after Cryo-Thermal Therapy. J. Immunother. Cancer 2022, 10, e005769. [Google Scholar] [CrossRef]
- Patel, R.; Sad, S. Transcription Factor Batf3 Is Important for Development of CD8+ T-Cell Response against a Phagosomal Bacterium Regardless of the Location of Antigen. Immunol. Cell Biol. 2016, 94, 378–387. [Google Scholar] [CrossRef]
- Smit, J.J.; Van Loveren, H.; Hoekstra, M.O.; Karimi, K.; Folkerts, G.; Nijkamp, F.P. The Slc11a1 (Nramp1) Gene Controls Efficacy of Mycobacterial Treatment of Allergic Asthma1. J. Immunol. 2003, 171, 754–760. [Google Scholar] [CrossRef] [Green Version]
- Smit, J.J.; Van Loveren, H.; Hoekstra, M.O.; Nijkamp, F.P.; Bloksma, N. Influence of the Macrophage Bacterial Resistance Gene Nramp1 (Slc11a1) on the Induction of Allergic Asthma in the Mouse. FASEB J. 2003, 17, 1–19. [Google Scholar] [CrossRef]
- Díaz-Molina, B.; Diaz-Bulnes, P.; Carvajal Palao, R.; Bernardo, M.J.; Rodriguez, R.M.; Corte-Iglesias, V.; Moris de la Tassa, C.; Lambert, J.L.; Suarez-Alvarez, B. Early Everolimus Initiation Fails to Counteract the Cytotoxic Response Mediated by CD8+ T and NK Cells in Heart Transplant Patients. Front. Immunol. 2018, 9, 2181. [Google Scholar] [CrossRef] [Green Version]
- Waldman, M.M.; Rahkola, J.T.; Sigler, A.L.; Chung, J.W.; Willett, B.A.S.; Kedl, R.M.; Friedman, R.S.; Jacobelli, J. Ena/VASP Protein-Mediated Actin Polymerization Contributes to Naïve CD8+ T Cell Activation and Expansion by Promoting T Cell–APC Interactions In Vivo. Front. Immunol. 2022, 13, 856977. [Google Scholar] [CrossRef] [PubMed]
- Estin, M.L.; Thompson, S.B.; Traxinger, B.; Fisher, M.H.; Friedman, R.S.; Jacobelli, J. Ena/VASP Proteins Regulate Activated T-Cell Trafficking by Promoting Diapedesis during Transendothelial Migration. Proc. Natl. Acad. Sci. USA 2017, 114, E2901–E2910. [Google Scholar] [CrossRef] [PubMed] [Green Version]
Characteristics | Univariable Analysis | Multivariable Analysis | ||
---|---|---|---|---|
HR (95% CI) | p-Value | HR (95% CI) | p-Value | |
Age | ||||
≤60 | reference | reference | ||
>60 | 1.36 (1.05–1.76) | * | 1.20 (0.89–1.60) | ns |
Tumor status | ||||
Tumor free | reference | reference | ||
With tumor | 8.39 (4.55–15.46) | *** | 9.18 (4.49–18.79) | *** |
Clinical stage | ||||
I + II | reference | |||
III + IV | 2.13 (0.95–4.81) | ns | ||
Venous invasion | ||||
No | reference | |||
Yes | 0.90 (0.49–1.65) | ns | ||
Lymphatic invasion | ||||
No | reference | |||
Yes | 1.39 (0.82–2.34) | ns | ||
Residual disease | ||||
≤10 mm | reference | reference | ||
>10 mm | 1.50 (1.12–2.00) | ** | 1.19 (0.87–1.63) | ns |
Risk group | ||||
Low | reference | reference | ||
High | 1.80 (1.39–2.34) | *** | 1.61 (1.20–2.15) | ** |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Zhang, C.; Qin, C.; Lin, Y. Development and Validation of a Prognostic Risk Model Based on Nature Killer Cells for Serous Ovarian Cancer. J. Pers. Med. 2023, 13, 403. https://doi.org/10.3390/jpm13030403
Zhang C, Qin C, Lin Y. Development and Validation of a Prognostic Risk Model Based on Nature Killer Cells for Serous Ovarian Cancer. Journal of Personalized Medicine. 2023; 13(3):403. https://doi.org/10.3390/jpm13030403
Chicago/Turabian StyleZhang, Chengxi, Chuanmei Qin, and Yi Lin. 2023. "Development and Validation of a Prognostic Risk Model Based on Nature Killer Cells for Serous Ovarian Cancer" Journal of Personalized Medicine 13, no. 3: 403. https://doi.org/10.3390/jpm13030403